Monocyte Activation Test (MAT) Strategy & Method Development

CellMade engineers tailored, human-relevant pyrogen testing strategies specifically designed for complex biopharmaceutical modalities that bypass or invalidate legacy LAL/BET assays. By leveraging human monocytic cell models, our advanced development workflows measure total pyrogenic load—detecting both bacterial endotoxins and broad-spectrum non-endotoxin pyrogens (NEPs) in a single, physiologically accurate system. From liposomal formulations and gene therapies to medical devices, we establish optimal assay sensitivity, define precise dilution boundaries, and engineer robust testing protocols fully aligned with European Pharmacopoeia (Ph. Eur. 2.6.30) guidelines to guarantee patient safety and regulatory acceptance.

• Total Pyrogenic Load Assessment: Comprehensive microscale screening capable of simultaneously quantifying Gram-negative bacterial endotoxins and non-endotoxin pyrogens (NEPs) originating from Gram-positive bacteria, viruses, molds, and yeasts.

• Complex Modality Optimization: Customized MAT assay protocols developed specifically for interference-prone formulations, including vaccines, cell and gene therapies (AAVs/mRNAs), blood products, liposomes, and complex biologics.

• Pyrogen Standard Curve & Sensitivity Mapping: Defining Maximum Valid Dilution (MVD) parameters, baseline cytokine cut-offs, and limit-of-detection profiles tailored to Ph. Eur. 2.6.30 regulatory standards.

• Medical Device & Extractables Pyrogenicity: Specialized extraction protocols and leachable/extractable pyrogen testing engineered for medical devices, combination products, and raw material contact surfaces.